Evidence map›Paper›PMID 36179129›Full record

ArticleInflammatory bowel diseases2023

Concordance and Discordance Between Patient-reported Remission, Patient-reported Outcomes, and Physician Global Assessment.

Kendra J Kamp, Stephen E Hawes, Chung Sang Tse, Siddharth Singh, Nhu Dang, Ridhima Oberai, S Alandra Weaver, Gil Y Melmed, Corey A Siegel, Welmoed K van Deen and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Patient-reported outcome measures applied in chronic diseases relevant to asthma remission: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Kendra J KampUniversity of Washington, Seattle, WA, United States.ORCID 0000-0002-7753-3564
Stephen E HawesUniversity of Washington, Seattle, WA, United States.
Chung Sang TseUniversity of California - San Diego, San Diego, CA, United States.
Siddharth SinghUniversity of California - San Diego, San Diego, CA, United States.ORCID 0000-0002-2640-7269
Nhu DangBrown University, Providence, RI, United States.
Ridhima OberaiCrohn's and Colitis Foundation, New York, NY, United States.
S Alandra WeaverCrohn's and Colitis Foundation, New York, NY, United States.
Gil Y MelmedCedars-Sinai Medical Center, Los Angeles, CA, United States.
Corey A SiegelDartmouth-Hitchcock Medical Center, Hanover, NH, United States.
Welmoed K van DeenErasmus School of Health Policy and Management, Rotterdam, the Netherlands.
IBD Qorus
Crohn's and Colitis Foundation · USUniversity of California San Diego · USUniversity of Washington · USBrown University · USCedars-Sinai Medical Center · USDartmouth–Hitchcock Medical Center · USErasmus University Rotterdam · NL

Funding

UNIVERSITY OF WASHINGTON GI TRAINING GRANTT32DK007742 · NIDDK · UNIVERSITY OF WASHINGTON · PI GRADY, WILLIAM MALLORY · 1996 to 2022
$4.7M
NIDDK NIH HHS T32 DK007742
6 · The paper itself

Abstract

backgroundAlthough validated patient-reported outcome (PRO) measurements can categorize patients with inflammatory bowel disease (IBD) into clinical remission or active disease, patients may have different definitions of remission. The purpose of this study was to compare patient-defined remission to remission based on PRO measures and physician global assessment (PGA) and to understand the clinical and demographic factors associated with disagreements.

methodsWe retrospectively analyzed 3257 de-identified surveys from 2004 IBD patients who consented to participate in the Crohn's and Colitis Foundation's IBD Qorus Learning Health System between September 2019 and February 2021. We used logistic regression models with generalized estimating equations to analyze the clinical and demographic factors (eg, age, disease duration, health confidence) associated with discordance between patient-defined remission (yes/no) and PRO-defined remission for ulcerative colitis (UC; PRO2: stool frequency, rectal bleeding) and Crohn's disease (CD; PRO-3: average number of liquid stools, abdominal pain, well-being).

resultsAmong patients with UC, overall concordance was 79% between patient self-report and PRO2-defined remission and 49% between patient self-report and PGA-defined remission. Among patients with CD, overall concordance was 69% between patient self-report and PRO3-defined remission and 54% between patient self-report and PGA-defined remission. Patients in PRO-defined remission were more likely to report active disease if they had IBD <5 years and low health confidence. Patients with PRO-defined active disease were more likely to report remission if they were not using prednisone and had high health confidence.

conclusionDiscordance exists between how remission is defined by patients, PRO measures, and PGA.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesPhysiciansHumansPatient Reported Outcome MeasuresRetrospective Studiesinflammatory bowel diseasepatient-reported outcomesremission

Identifiers

PMID36179129
PMCPMC10393067
OpenAlexW4298124889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.